Reducing Cardiovascular Risk in Men Receiving Androgen Deprivation Therapy
Speakers: Neal D. Shore, MD, FACSJavid Moslehi, MD, Cardiologist and Myocyte Biologist
Duration: 30 minutes
Presented on: November 9, 2021
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACSNeal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Javid Moslehi, MD
Javid Moslehi, MD
Cardiologist and Myocyte BiologistJavid Moslehi, MD, is a cardiologist and myocyte biologist as well as the William Grossman Distinguished Professor in Cardiology and Chief, Section of Cardio-Oncology, Immunology, and Metabolism at UCSF. Recently, he was named the first chair of the American Heart Association cardio-oncology subcommittee. Moreover, Dr. Moslehi has established a Graduate Medical Education (GME) approved fellowship at UCSF to train the next generation of physician-scientists in the field of cardio-oncology, which is his clinical focus. Over the last several years, Dr. Moslehi’s laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. Furthermore, he is an elected member of American Society of Clinical Investigation.
Reducing Cardiovascular Risk in Men Receiving Androgen Deprivation Therapy
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Pfizer Inc and Myovant Sciences Ltd.
DATE OF RELEASE/EXPIRATIONThis activity will be released on November 9 and is valid until May 9, 2022. Requests for credit must be made no later than May 9, 2022.
TARGET AUDIENCEThe educational design of this activity addresses the needs of urologists, medical oncologists, radio-oncologists, radiologists, cardiologists, and cardio-oncologists, and other allied health members managing patients on ADTs.
STATEMENT OF NEED/PROGRAM OVERVIEWAs new androgen deprivation therapy (ADT) medications continue to be developed for the treatment of advanced prostate cancer, cardiologists, cardio-oncologists, and other clinicians need to better understand the specific cardiovascular risks related to treatment. Patient-centered care for men with prostate cancer depends on a multidisciplinary approach that considers cardiovascular risk during treatment.
Faculty experts will discuss the cardiovascular risks associated with ADT and share methods to lower those risks. Clinicians will learn how to effectively communicate the risks and benefits of treatment to their patients and discover strategies to mitigate that risk that can be shared with patients. The importance of including cardiologists and cardio-oncologists on the care team will also be reviewed.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Review the cardiovascular risks of ADT
- Discuss cardiovascular risk management strategies for patients undergoing ADT
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 30 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURE OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics
Consulting Fee: Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme, Speciality Networks, Sesen Bio, Tolmar, Urogen Speakers’ Bureau: Astellas, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Janssen, Merck, Pfizer, Guardant Health Javid Moslehi, MD
William Grossman Distinguished Professor in Cardiology
Section Chief, Cardio-Oncology, Immunology and Metabolism
Associate Professor in Residence
University of California, San Francisco (UCSF) School of Medicine
Consulting Fee: Novartis, Pfizer, Bristol-Myers Squibb, Takeda/Millennium, Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi Sankyo, Regeneron, Myokardia, Redux, Audentes Pharmaceuticals, AstraZeneca, Deciphera, Ipsen, Boston Biomedical, ImmunoCore, Nektar, Intrexon, GlaxoSmithKline, Janssen, Myovant, Amgen, Boehringer, Cytokinetics
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Kim Rodriguez Nothing to disclose Tariqa Ackbarali Nothing to disclose Alissa Yost Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Info@CardioCareLive.com.